The Zhitong Finance App learned that Guoyuan International released a research report stating that it gave Shenwei Pharmaceutical (02877.HK) a “buy” rating. The target price is HK$10.04, which corresponds to the price-earnings ratio of 8 times 2026, an increase of 29.4% over the current price. The bank estimates that the company's revenue from 2026 to 2028 will be RMB 2.67 billion, RMB 2.83 billion and RMB 3.16 billion, respectively, and net profit of RMB 890 million, 960 million and RMB 1.09 billion, respectively. As new drugs continue to be marketed, the company's product structure will be optimized. The company's oral products account for 72.4%, and injections account for 27.6%. The product structure is reasonable and the resistance to risk is improved.

The Zhitong Finance App learned that Guoyuan International released a research report stating that it gave Shenwei Pharmaceutical (02877.HK) a “buy” rating. The target price is HK$10.04, which corresponds to the price-earnings ratio of 8 times 2026, an increase of 29.4% over the current price. The bank estimates that the company's revenue from 2026 to 2028 will be RMB 2.67 billion, RMB 2.83 billion and RMB 3.16 billion, respectively, and net profit of RMB 890 million, 960 million and RMB 1.09 billion, respectively. As new drugs continue to be marketed, the company's product structure will be optimized. The company's oral products account for 72.4%, and injections account for 27.6%. The product structure is reasonable and the resistance to risk is improved.